JP2016193932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016193932A5 JP2016193932A5 JP2016133918A JP2016133918A JP2016193932A5 JP 2016193932 A5 JP2016193932 A5 JP 2016193932A5 JP 2016133918 A JP2016133918 A JP 2016133918A JP 2016133918 A JP2016133918 A JP 2016133918A JP 2016193932 A5 JP2016193932 A5 JP 2016193932A5
- Authority
- JP
- Japan
- Prior art keywords
- binding domain
- dose
- pharmaceutical composition
- administered
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003862 glucocorticoid Substances 0.000 claims description 20
- 229960003957 dexamethasone Drugs 0.000 claims description 11
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 11
- 230000000926 neurological effect Effects 0.000 claims description 11
- 230000002411 adverse Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 4
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 229960003008 blinatumomab Drugs 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 206010048962 Brain oedema Diseases 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 208000004547 Hallucinations Diseases 0.000 claims description 2
- 208000020764 Sensation disease Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 208000006752 brain edema Diseases 0.000 claims description 2
- 208000027765 speech disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 208000008035 Back Pain Diseases 0.000 claims 2
- 206010003062 Apraxia Diseases 0.000 claims 1
- 208000007542 Paresis Diseases 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41222910P | 2010-11-10 | 2010-11-10 | |
| US61/412,229 | 2010-11-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538125A Division JP6023717B2 (ja) | 2010-11-10 | 2011-10-27 | Ｃｄ３特異的結合ドメインによって引き起こされる有害作用の予防 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016193932A JP2016193932A (ja) | 2016-11-17 |
| JP2016193932A5 true JP2016193932A5 (cg-RX-API-DMAC7.html) | 2017-06-08 |
| JP6189491B2 JP6189491B2 (ja) | 2017-08-30 |
Family
ID=45044532
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538125A Active JP6023717B2 (ja) | 2010-11-10 | 2011-10-27 | Ｃｄ３特異的結合ドメインによって引き起こされる有害作用の予防 |
| JP2016133918A Active JP6189491B2 (ja) | 2010-11-10 | 2016-07-06 | Ｃｄ３特異的結合ドメインによって引き起こされる有害作用の予防 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538125A Active JP6023717B2 (ja) | 2010-11-10 | 2011-10-27 | Ｃｄ３特異的結合ドメインによって引き起こされる有害作用の予防 |
Country Status (32)
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| EP3831386A1 (en) | 2010-11-10 | 2021-06-09 | Amgen Research (Munich) GmbH | Prevention of adverse effects caused by cd3 specific binding domains |
| AU2012247762B2 (en) * | 2011-04-28 | 2017-07-06 | Amgen Research (Munich) Gmbh | Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at risk for potential adverse effects |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| HRP20191865T1 (hr) * | 2013-01-14 | 2020-01-10 | Xencor, Inc. | Novi heterodimerni proteini |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| LT2951203T (lt) * | 2013-03-15 | 2019-09-10 | Xencor, Inc. | Heterodimeriniai baltymai |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| CN106029696B (zh) | 2013-12-17 | 2020-07-28 | 基因泰克公司 | 抗cd3抗体及使用方法 |
| SG11201607983YA (en) | 2014-03-28 | 2016-10-28 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
| TW201625690A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗－ｃｌｌ－１抗體及免疫結合物 |
| CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
| RS62332B1 (sr) | 2014-11-26 | 2021-10-29 | Xencor Inc | Heterodimerna antitela koja vezuju cd3 i cd20 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| RS59203B1 (sr) | 2014-12-05 | 2019-10-31 | Hoffmann La Roche | Anti-cd79b antitela i postupci primene |
| US10428155B2 (en) | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| PE20240218A1 (es) | 2015-06-16 | 2024-02-16 | Genentech Inc | Anticuerpos madurados por afinidad y humanizados para fcrh5 |
| JP6996983B2 (ja) | 2015-06-16 | 2022-02-21 | ジェネンテック， インコーポレイテッド | 抗ｃｌｌ－１抗体及び使用方法 |
| EP3322735A4 (en) | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| CN106810610A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| CN106810611A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| US11623957B2 (en) | 2015-12-07 | 2023-04-11 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
| UY37105A (es) | 2016-02-03 | 2017-09-29 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| IL263542B2 (en) | 2016-06-14 | 2024-10-01 | Xencor Inc | Bispecific antibodies inhibit immunological checkpoint |
| CN116063545A (zh) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| MA46534A (fr) | 2016-10-14 | 2019-08-21 | Xencor Inc | Protéines de fusion fc hétérodimères il15/il15r |
| US11466094B2 (en) | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
| EP4279136A3 (en) * | 2016-12-03 | 2024-03-20 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| KR20180090600A (ko) | 2017-02-03 | 2018-08-13 | 주식회사 대유위니아 | 전기밥솥 |
| EP4353818A3 (en) | 2017-02-27 | 2024-06-19 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| US11421278B2 (en) * | 2017-08-30 | 2022-08-23 | Bristol-Myers Squibb Company | Method to monitor pharmacodynamic responses mediated by in vivo administration of glucocorticoids |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN112272563A (zh) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | 使用新颖抗pd-1序列的双特异性和单特异性抗体 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| IL275426B2 (en) | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| CN118772288A (zh) | 2018-02-08 | 2024-10-15 | 豪夫迈·罗氏有限公司 | 双特异性抗原结合分子和使用方法 |
| AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
| JP7612571B2 (ja) | 2018-10-03 | 2025-01-14 | ゼンコア インコーポレイテッド | Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質 |
| BR112021016955A2 (pt) | 2019-03-01 | 2021-11-23 | Xencor Inc | Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico |
| JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
| KR102878895B1 (ko) | 2019-05-21 | 2025-10-31 | 노파르티스 아게 | Cd19 결합 분자 및 이의 용도 |
| RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
| AR120741A1 (es) | 2019-12-13 | 2022-03-16 | Genentech Inc | Anticuerpos anti-ly6g6d y métodos de uso |
| US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| US20250074981A1 (en) * | 2021-04-06 | 2025-03-06 | Memorial Sloan-Kettering Cancer Center | Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer |
| CA3218578A1 (en) | 2021-05-14 | 2022-11-17 | Carol Elaine O'hear | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| WO2023057650A1 (en) | 2021-10-10 | 2023-04-13 | Centre Hospitalier Universitaire Vaudois (Chuv) | A method for predicting side effects of drugs and vaccines |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| DE69909459T2 (de) | 1998-04-21 | 2004-05-27 | Micromet Ag | Cd19xcd3 spezifische polypeptide und deren verwendung |
| US20070224191A1 (en) | 2002-12-05 | 2007-09-27 | Pdl Biopharma, Inc. | Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies |
| RU2005141512A (ru) | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| PL1976886T3 (pl) | 2005-12-16 | 2015-06-30 | Amgen Res Munich Gmbh | Środki i metody do leczenia chorób nowotworowych |
| CN101331151A (zh) * | 2005-12-16 | 2008-12-24 | 麦克罗梅特股份公司 | 治疗肿瘤性疾病的方式和方法 |
| PL2155788T3 (pl) | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
| PT2520590T (pt) | 2007-04-03 | 2018-11-14 | Amgen Res Munich Gmbh | Domínio de ligação específico de espécies cruzadas |
| SG182234A1 (en) | 2007-04-03 | 2012-07-30 | Amgen Res Munich Gmbh | Cross-species-specific cd3-epsilonbinding domain |
| US9308257B2 (en) | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| CA2742249C (en) * | 2008-11-07 | 2020-07-21 | Micromet Ag | Treatment of acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody |
| AU2010311559B2 (en) * | 2009-10-27 | 2016-07-07 | Amgen Research (Munich) Gmbh | Dosage regimen for administering a CD19xCD3 bispecific antibody |
| LT3018145T (lt) | 2010-10-27 | 2018-05-10 | Amgen Research (Munich) Gmbh | Priemonės ir būdai dlbcl gydymui |
| EP3831386A1 (en) | 2010-11-10 | 2021-06-09 | Amgen Research (Munich) GmbH | Prevention of adverse effects caused by cd3 specific binding domains |
-
2011
- 2011-10-27 EP EP20209362.1A patent/EP3831386A1/en active Pending
- 2011-10-27 ES ES11788077T patent/ES2627538T5/es active Active
- 2011-10-27 JP JP2013538125A patent/JP6023717B2/ja active Active
- 2011-10-27 CN CN201810044039.1A patent/CN108403702A/zh active Pending
- 2011-10-27 LT LTEP11788077.3T patent/LT2637670T/lt unknown
- 2011-10-27 EP EP11788077.3A patent/EP2637670B2/en active Active
- 2011-10-27 SM SM20170250T patent/SMT201700250T1/it unknown
- 2011-10-27 EP EP17159560.6A patent/EP3228315B1/en active Active
- 2011-10-27 HR HRP20170814TT patent/HRP20170814T4/hr unknown
- 2011-10-27 FI FIEP11788077.3T patent/FI2637670T4/fi active
- 2011-10-27 KR KR1020137014669A patent/KR101891845B1/ko active Active
- 2011-10-27 SG SG2013034731A patent/SG190174A1/en unknown
- 2011-10-27 PH PH1/2013/500940A patent/PH12013500940A1/en unknown
- 2011-10-27 MY MYPI2013001611A patent/MY173177A/en unknown
- 2011-10-27 PL PL11788077.3T patent/PL2637670T5/pl unknown
- 2011-10-27 SI SI201131196T patent/SI2637670T2/sl unknown
- 2011-10-27 ME MEP-2017-104A patent/ME02722B/me unknown
- 2011-10-27 SG SG10201508789TA patent/SG10201508789TA/en unknown
- 2011-10-27 CN CN201180064622.5A patent/CN103533943B/zh active Active
- 2011-10-27 US US13/884,497 patent/US10130638B2/en active Active
- 2011-10-27 DK DK11788077.3T patent/DK2637670T4/da active
- 2011-10-27 WO PCT/EP2011/068862 patent/WO2012062596A1/en not_active Ceased
- 2011-10-27 HU HUE11788077A patent/HUE032782T2/en unknown
- 2011-10-27 ES ES17159560T patent/ES2842937T3/es active Active
- 2011-10-27 EA EA201390621A patent/EA026075B1/ru not_active IP Right Cessation
- 2011-10-27 AU AU2011328393A patent/AU2011328393B2/en active Active
- 2011-10-27 NZ NZ610034A patent/NZ610034A/en unknown
- 2011-10-27 PT PT117880773T patent/PT2637670T/pt unknown
- 2011-10-27 UA UAA201307130A patent/UA113397C2/uk unknown
- 2011-10-27 RS RS20170458A patent/RS55995B2/sr unknown
- 2011-10-27 CA CA2816668A patent/CA2816668C/en active Active
-
2013
- 2013-05-09 CL CL2013001287A patent/CL2013001287A1/es unknown
- 2013-05-09 IL IL226268A patent/IL226268B/en active IP Right Grant
- 2013-06-10 CR CR20130278A patent/CR20130278A/es unknown
- 2013-06-10 TN TNP2013000250A patent/TN2013000250A1/fr unknown
- 2013-06-10 MA MA35999A patent/MA34726B1/fr unknown
-
2016
- 2016-07-06 JP JP2016133918A patent/JP6189491B2/ja active Active
-
2017
- 2017-03-29 AU AU2017202079A patent/AU2017202079B2/en active Active
- 2017-05-08 CY CY20171100491T patent/CY1118894T1/el unknown
-
2018
- 2018-01-25 IL IL257164A patent/IL257164B/en active IP Right Grant
- 2018-02-07 AU AU2018200915A patent/AU2018200915B2/en active Active
- 2018-10-11 US US16/157,985 patent/US11633408B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016193932A5 (cg-RX-API-DMAC7.html) | ||
| Andrade et al. | The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments | |
| Stark et al. | Interleukin-6 and the development of social disruption-induced glucocorticoid resistance | |
| Sun et al. | Review of drugs for Alzheimer's disease | |
| Molinuevo et al. | Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias | |
| HRP20170814T1 (hr) | Prevencija nuspojava uzrokovanih cd3 specifičnim veznim domenama | |
| D’Andrea et al. | Efficacy of Ginkgolide B in the prophylaxis of migraine with aura | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| Chan et al. | Amantadine improves gait in PD patients with STN stimulation | |
| RU2013154699A (ru) | Сцилло-инозитол для применения в лечении поведенческих и психических расстройств | |
| JP2018537513A5 (cg-RX-API-DMAC7.html) | ||
| Morgan et al. | TNF signalling via the TNF receptors mediates the effects of exercise on cognition-like behaviours. | |
| Chang et al. | Targeting the prodromal stage of spinocerebellar ataxia type 17 mice: G-CSF in the prevention of motor deficits via upregulating chaperone and autophagy levels | |
| Coss-Rovirosa et al. | Severe fingolimod rebound syndrome after switching to cladribine treatment | |
| Iranmanesh et al. | Efficiency of citicoline in increasing muscular strength of patients with nontraumatic cerebral hemorrhage: a double-blind randomized clinical trial | |
| WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2020064979A1 (en) | Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases | |
| JP2020505448A5 (cg-RX-API-DMAC7.html) | ||
| Romero-Carbente et al. | Role of main neuroendocrine pathways activated by swim stress on mast cell-dependent peritoneal TNF production after LPS administration in mice | |
| US11571433B2 (en) | Methods for treating memory impairment and cognitive dysfunction | |
| Hollister et al. | CHLORPROMAZINE ALONE AND WITH RESERPINE—Use in the Treatment of Mental Diseases | |
| JP2019524889A5 (cg-RX-API-DMAC7.html) | ||
| Hidaka et al. | Involvement of α4β2 nicotinic acetylcholine receptors in working memory impairment induced by repeated electroconvulsive seizures in rats |